Phase 3 Clinical Trials With Primary Completion Dates in July 2023

This is a list of Phase 3 trials with primary completion dates in July 2023 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
ACAD ACADIA Pharmaceuticals Inc. 2023-07-01 Phase 3 NCT04776746 Open-Label Extension Study of Trofinetide for Rett Syndrome
ALLK Allakos Inc. 2023-07-01 Phase 3 NCT04620811 An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)
ARAV Aravive, Inc. 2023-07-01 Phase 3 NCT04729608 Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer
BLCO Bausch + Lomb Corporation 2023-07-01 Phase 3 NCT05360784 "Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Redness"
CRNX Crinetics Pharmaceuticals, Inc. 2023-07-01 Phase 3 NCT04837040 A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly
IBRX ImmunityBio, Inc. 2023-07-01 Phase 3 NCT03520686 QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC.
IONS Ionis Pharmaceuticals, Inc. 2023-07-01 Phase 3 NCT04568434 A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS)
KRTX Karuna Therapeutics, Inc. 2023-07-01 Phase 3 NCT04820309 An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)
RLMD Relmada Therapeutics, Inc. 2023-07-01 Phase 3 NCT04855760 Safety of REL-1017 for Major Depressive Disorder
SUPN Supernus Pharmaceuticals, Inc. 2023-07-01 Phase 3 NCT04143217 Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD
TBPMF Tetra Bio-Pharma Inc. 2023-07-01 Phase 3 NCT04001010 Safety and Efficacy of Inhaled Synthetic THC/CBD for Improving Physical Functioning and for Modulating Cachexia Progression in Patients With Advanced Cancer and Associated Cachexia